Immune‐mediated thrombotic thrombocytopenic purpura in a Jehovah’s Witness – Effectiveness of incorporating extracorporeal immunoadsorption to caplacizumab,steroids and rituximab |
| |
| Authors: | Teresa Marta Cardesa‐ Salzmann,Bernhard Stephan,Arne Simon,Rhoikos Furtwä ngler,Dominik Schö ndorf,Sabine Heine,Eyad Torfah,Margaux Lux,Sonja Meyer,Norbert Graf |
| |
| Affiliation: | 1. Department of Pediatric Hematology & Oncology, Universitätsklinikum des Saarlandes, Homburg Germany ; 2. Department of Hemostaseology and Transfusion Medicine, Universitätsklinikum des Saarlandes, Homburg Germany |
| |
| Abstract: | We report the case of a Jehovah''s Witness adolescent patient with immune‐mediated thrombotic thrombocytopenic purpura after SARS‐Cov2 infection successfully treated without therapeutic plasma exchange (TPE) using caplacizumab, corticosteroids, rituximab, and extracorporeal immunoadsorption (EIA). Further patients for whom TPE is not an option might benefit from this approach. |
| |
| Keywords: | caplacizumab, immune‐ mediated TTP – SARS‐ Cov2, immunoadsorption, Jehovah''s Witness, therapy without therapeutic plasma exchange |
|
|
